Stock NOVA NOVA MENTIS LIFE SCIENCE CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Company Nova Mentis Life Science Corp.

Equities

NOVA

CA66980V1067

Biotechnology & Medical Research

Delayed Canadian Securities Exchange
Other stock markets
 03:38:53 2024-04-25 pm EDT 		5-day change 1st Jan Change
0.015 CAD 0.00% Intraday chart for Nova Mentis Life Science Corp. +50.00% -25.00%
Apr. 08 Nova Mentis Life Science Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Feb. 26 Nova Mentis Life Science Corp. Announces the Appointment of Steve Loutskou to the Board of Directors CI

Business Summary

Nova Mentis Life Science Corp. is a Canadian biotechnology company. The Company is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. The Company has orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS). Its focus is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS. Its core scientific focus is on chronic neuroinflammatory conditions, which fall under three categories: neurodevelopmental, neurometabolic, and neurodegenerative. The Company operates in one segment, being research and development of psilocybin, and in one geographic area, being Canada, through its wholly owned subsidiaries, Nova Mentis Biotech Corp., and SwabAi Diagnostics Inc.

Managers

Managers TitleAgeSince
William Rascan CEO
 Chief Executive Officer - 12-05-15
Rebecca Hudson DFI
 Director of Finance/CFO - 21-12-29
Kelly Pladson ADM
 Chief Administrative Officer 42 17-01-31
Robert W.E Laurie
- -
Michael Barcellona PRN
 Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Derek Ivany CHM
 Chairman 41 23-01-17
William Rascan CEO
 Chief Executive Officer - 12-05-15

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 148,168,660 130,973,660 ( 88.39 %) 0 88.39 %

Shareholders

NameEquities%Valuation
Derek Ivany
10.78 %
15,858,000 10.78 % 222 012 $
William Rascan
1.499 %
2,206,375 1.499 % 30 889 $
Georg Hochwimmer
1.261 %
1,856,500 1.261 % 25 991 $
Rebecca Hudson
0.4077 %
600,000 0.4077 % 8 400 $
Steven Feldman
0.0679 %
100,000 0.0679 % 1 400 $
Jacqueline McConnell
0.000000 %
0 0.000000 % - $
Stephen Glazer
0.000000 %
0 0.000000 % - $

Company contact information

Nova Mentis Life Science Corp.

838 West Hasting Street Suite 700

V6C 0A6, Vancouver

+778-819-0244

http://www.novamentis.ca
address Nova Mentis Life Science Corp.(NOVA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NOVA MENTIS LIFE SCIENCE CORP. Stock Nova Mentis Life Science Corp.
-25.00% 1.63M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+2.04% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+47.58% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+11.20% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.19% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.91% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.58% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.08% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.59% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NOVA Stock
  4. Company Nova Mentis Life Science Corp.